Clinical Researchin New Orleans, LA | Audubon Dermatology

Topical Berdazimer Gel, A Nitric Oxide-Releasing Macromolesule -  a phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study comparing the efficacy and safety of SB206 and vehicle gel applied once daily in the treatment of molluscum contagiosum

Topical Ivermectin - a multi-center, double-blind, randomized, placebo controlled, patallel-group study, comparing 1% ivermectin cream (Taro Pharmaceuticals U.S.A. Inc.) to 1% ivermectin cream (Soolantra) and both active treatments to a placebo control in the treatment of moderate to severe facial rosacea

Poly-L-Lactic Acid Implant - a randomized, evaluator-blinded, no-treatment controlled, multi-center study to evaluate the effectiveness and safety of Sculptra Aesthetic for correction of cheek wrinkles

Topical PDE-4 Inhibitor - a phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of 0.3% ARQ-151 cream administered daily in subjects with chronic plaque psoriasis

Topical Non-Steroid, Therapeutic AhR-Modulating Agent - a long-term, open-label extension study to evaluate the safety and efficacy of 1% tapinarof cream for the treatment of plaque psoriasis in adults

Topical PDE-4 Inhibitor - a phase 3, multi-center, open-label extension study of the long-term safety of 0.3% ARQ-151 Cream in subjects with chronic plaque psoriasis

Oral Kappa Receptor Agonist - a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral difelikefalin (CR845) for moderate to severe pruritus in adults subjects with atopic dermatitis

Topical JAK inhibitor - a phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety study of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subject with Moderate-to-Severe Plaque Psoriasis

A Double-Blind, Randomized, Vehicle-Controlled, Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study with an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis

Injectable Proteinase Hydrolyzes, the Triple-Helical Region of Collagen - A phase 3B, open-label, long-term study to evaluate the safety and temporal pattern of response of EN3835 In the treatment of edematous fibrosclerotic panniculopathy

IL-17 Inhibitor - a multi-center, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy

IL-17 Inhibitor - a multi-center, randomized, double blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® (Pimecrolimus) Cream, 1% in Patients with Mild to Moderate Atopic Dermatitis

An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects with Acne Vulgaris

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris

A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea

A Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects with Acne Vulgaris

An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)

A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receiving topical corticosteroids

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp

A Randomized, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis

A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis

A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks

A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea